Latest Boardroom Shifts News

Page 36 of 170
Touch Ventures Limited reported a $4.6 million net loss for 2025, driven by investment impairments and foreign exchange impacts, while appointing Gannet Capital as its new investment manager to revamp its portfolio strategy.
Claire Turing
Claire Turing
13 Feb 2026
AVITA Medical reported an 11% increase in sales revenue for 2025, driven by deeper market penetration and new product launches, while reducing its net loss by 21%. The company secured a $60 million senior secured credit facility but flagged substantial doubt about its ability to continue as a going concern.
Ada Torres
Ada Torres
13 Feb 2026
Regal Asian Investments Limited (ASX, RG8) has updated its Dividend Reinvestment Plan, eliminating the minimum participation requirement and streamlining administrative processes for shareholders.
Claire Turing
Claire Turing
13 Feb 2026
Alkane Resources Ltd has reported a remarkable half-year surge in revenue and profit, driven by its strategic merger with Mandalay Resources Corporation and soaring gold prices.
Maxwell Dee
Maxwell Dee
13 Feb 2026
PeopleIN Limited has appointed co-founder Tom Reardon as its new CEO and Managing Director, signaling continuity in leadership as the company reports a robust unaudited EBITDA of $16.1 million.
Victor Sage
Victor Sage
13 Feb 2026
Minbos Resources has appointed Rob Newbold as Acting CEO following the resignation of Lindsay Reed, while grappling with administrative and shareholder challenges delaying its key phosphate project in Angola.
Maxwell Dee
Maxwell Dee
13 Feb 2026
Dusk Group Limited has reported a solid 5.2% increase in net profit for the half year ended December 2025, alongside a 5.1% rise in revenue. The company also announced a fully franked interim dividend doubling the prior payout, signalling confidence in its retail operations.
Logan Eniac
Logan Eniac
13 Feb 2026
Podium Minerals has disclosed the initial securities interests of its newly appointed directors, highlighting a significant allocation of performance rights to Gary Humphries while Neal Froneman holds none.
Maxwell Dee
Maxwell Dee
12 Feb 2026
Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.
Ada Torres
Ada Torres
12 Feb 2026
Elixinol Wellness reported a 9.5% revenue increase in Q4 FY25 alongside a 30% reduction in operating costs, setting a clear path to profitability under fresh executive leadership.
Victor Sage
Victor Sage
12 Feb 2026
ASX Limited reported robust half-year results with an 11.2% rise in operating revenue and a steady net profit, while advancing its technology upgrade and responding to regulatory scrutiny.
Claire Turing
Claire Turing
12 Feb 2026
ASX Limited has posted a solid 8.3% increase in net profit for the half-year ending December 2025, while announcing a reduced dividend payout and the planned departure of its CEO. The company is navigating regulatory scrutiny and investing heavily in technology upgrades.
Claire Turing
Claire Turing
12 Feb 2026